45 results about "Parental strain" patented technology

Through screening of a Zymomonas mutant library the himA gene was found to be involved in the inhibitory effect of acetate on Zymomonas performance. Xylose-utilizing Zymomonas strains further engineered to reduce activity of the himA gene were found to have increased ethanol production in comparison to a parental strain, when cultured in mixed-sugars medium comprising xylose, and, in particular, in the presence of acetate.

Reduced genome strains of E. coli MGl 655 are described. In various embodiments, the strains have one or more of equal or improved growth rate, transformation efficiency, protein expression, DNA production, DNA yield and/or DNA quality compared to the parental strain and commercially available strains.

Described are methods of reducing the amount of byproduct organic acids during fermentation of an organism, based on expression of a heterologous malonyl-CoA synthetase. A polyunsaturated fatty acid [“PUFA”]-producing strain of the oleaginous yeast Yarrowia lipolytica was engineered to express a heterologous malonyl-CoA synthetase gene. The expression did not effect the production of PUFAs, but did result in a reduced amount of malonates when compared to the amount of malonates produced in the parental strain not expressing malonyl-CoA synthetase.

African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs. Control of ASF has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. Among viral genes reported to be involved in virulence are components of the multi gene family (MGF). Here we report the construction of a recombinant ΔMGF virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G ΔMGF administered intramuscularly (IM) to swine at either 10² or 10⁴ HAD₅₀ are completely attenuated; the inoculated animals are completely asymptomatic. Animals infected with 10² or 10⁴ HAD50 of ASFV-G ΔMGF are protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.

The invention of molecular labeling method of Pyricularia grisea avirulent gene belongs to the field of agricultural biotechnology. The molecular labeling technology includes performing molecular labeling to avirulent gene though assessment from two parental strains and filial generation groups of Pyricularia grisea. M355-356 labeled by SSR near NO. 1 chromosome telomere links with avirulent gene Avr-Pit with a genetic distance of 2.3cm; S487 labeled by RAPD located near NO. 7 chromosome telomere links with avirulent gene Avr-Pia with a genetic distance of 3.5cm; S361 labeled by m677-678 and RAPD located at middle of N0. 3 chromosome telomere links with Pyricularia grisea specified avirulent gene PRE1 with genetic distances of 5.9cm and 6.4. The invention can not only make use of the nontoxic gene marker as gene probe, but also set foundations for further clone of the gene through physical mapping.

This invention relates to the production of chemicals by fermentation with a microorganism in which the fermentation medium contains the sugar sucrose. As a specific example, succinic acid is produced from a sucrose-containing renewable feedstock through fermentation using a biocatalyst. Examples of such a biocatalyst include microorganisms that have been enhanced in their ability to utilize sucrose as a carbon and energy source. The biocatalysts of the present invention are derived from the genetic manipulation of parental strains that were originally constructed with the goal to produce one or more chemicals (for example succinic acid and/or a salt of succinic acid) at a commercial scale using feedstocks other than sucrose. The genetic manipulations of the present invention involve the introduction of exogenous genes involved in the transport and metabolism of sucrose into the parental strains. The genes involved in the transport and metabolism of sucrose can also be introduced into a microorganism prior to developing the organism to produce a particular chemical. The genes involved in the transport and metabolism of sucrose can also be used to augment or improve the sucrose transport and metabolism by strains already known to have some ability for sucrose utilization in biological fermentation.

This invention relates to the production of succinic acid and other chemicals derived from phosphoenolpyruvate (PEP) by fermentation with a microorganism in which the fermentation medium contains one or more sugars, and in which one or more of the sugars is imported into the cell by facilitated diffusion. As a specific example, succinic acid is produced from a glucose-containing renewable feedstock through fermentation using a biocatalyst. Examples of such a biocatalyst include microorganisms that have been enhanced in their ability to utilize glucose as a carbon and energy source. The biocatalysts of the present invention are derived from the genetic manipulation of parental strains that were originally constructed with the goal to produce one or more chemicals (for example succinic acid and/or a salt of succinic acid) at a commercial scale using feedstocks that include, for example, glucose, fructose, or sucrose. The genetic manipulations of the present invention involve the introduction of exogenous genes involved in the transport and metabolism of glucose or fructose into the parental strains. The genes involved in the transport and metabolism of glucose or fructose can also be introduced into a microorganism prior to developing the organism to produce a particular chemical. The genes involved in the transport and metabolism of sucrose can also be used to augment or improve the efficiency of sugar transport and metabolism by strains already known to have some ability for glucose utilization in biological fermentations.

The invention belongs to the technical field of medical technology, relates to a preparation method for increasing CK (Compound K) yield of ginsenoside, and in particular relates to a preparation method for increasing the CK yield of ginsenoside by increasing the yield of a converted product through adjustment and control in a microbial conversion process. According to the preparation method, the yield of the converted product and the concentration of a primer are improved through metabolic regulation. The preparation method comprises the steps of: reconstructing ultraviolet mutagenesis of a parental strain, culturing in a high-concentration pseudo-ginseng stem and leave saponin culture medium, sieving in a directional manner to obtain a strain resisting to 1-5% of the total saponins of the pseudo-ginseng stems and leaves. Through the strain mutagenesis and the metabolic regulation, the concentration of the primer and the yield of the converted product are improved obviously, the final conversion rate is up to 43.63%, and the yield of the Compound K of the ginsenoside is improved by more than 80%. The preparation method for increasing CK yield of ginsenoside has practical significance for the industrial application of the microbial conversion.

The invention discloses a porcine parvovirus infectious cloning system stably carrying a genetic marker, a construction method and an application thereof. The blunt-end enzyme sites are introduced into an ITR sequence at both ends of a porcine parvovirus (PPV) genome, and an In-Fusion technology is used, and a non-sense mutation is introduced into a PPV intermediate sequence to obtain a PPV full-length infectious cloning plasmid carrying genetic marker and distinguished with a wild strain. The infectiou cloning plasmid constructed by a reverse heredity operation technology is used for transfection of PK15 cells in vitro, can induce the cells to generate the same cytopathic effect as the parental strain after continuous blind passage, and a rescue virus that having a similar growth trend asthe parent strain and carrying genetic marker can be rescued. The cloning system can quickly and conveniently perform base mutations at any position in the genome, and provides a convenient and effective tool for the subsequent development of attenuated vaccines and multiple vaccines of porcine parvovirus.

Mycobacterium bovis BCG is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are BCG strains that generate greater MHC class I presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's CD8+ T cell response against the transgenic protein following vaccination. The mycobacterial constructs and their respective t/ansposon mutant BCG strains exhibit increased immunogenicity that is several times greater than responses generated by the parental strain and other existing modified rBCG strains. Furthermore, upon introducing the SIV gag gene into these novel strains, we observed that these strains primed for increased CD8+ T cell responses in a heterologous prime/boost regimen, comparable to levels generated by plasmid DNA vaccines. Creation of a second generation rBCG vector that may be utilized as a vaccine vector for immunizing against a variety of pathogens.

Provided herein are fungi, such as Aspergillus niger, having a dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase (Alg3) gene genetic inactivation, increased expression of a loss of aflR expression A (Lae), or both. In some examples, such mutants have several phenotypes, including an increased production of citric acid relative to the parental strain. Methods of using the disclosed fungi to make citric acid are also provided, as are compositions and kits including the disclosed fungi.

This invention discloses a method for breeding pesticidal fungi with stable pathogenicity. The method comprises: (1) separating monospores of pesticidal fungi, mutagenizing on chlorate potato medium (KPS), punching to separate anti-chlorate mutants, and identifying with basic medium and KPS medium to obtain nitrate-utilization auxotrophic mutants (nit); (2) selecting nit mutants with high vegetative compatibility to obtain parental strains, collecting zygospores, and culturing to obtain heterocaryon; (3) staining the heterocaryon with Hoechest 33258, and observing to identify heterocaryosis. The pesticidal fungi have stable pathogenicity, and can prevent and treat pests in agriculture, forestry and stockbreeding.

Adaptive engineering of microorganisms to create mutants exhibiting high butanol tolerance and productivity. Mutant strains are obtained through the fermentation of parental strains in a fibrous bed bioreactor in the presence of butanol. Also provided are methods of producing butanol using mutant strains in ABE fermentation. Butanol production may be furthered by gas stripping and distillation. Also provided are mutant proteins for increasing butanol production in a microorganism.

The genomic DNA of Streptoverticillium sp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore, Streptoverticillium sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.

The invention relates to a mutant of Bacillus thuringiensis which produces a larger amount of crystal delta-endotoxin with a greater pesticidal activity as compared to the corresponding parental strain. The mutant may also have a larger crystal size as compared to the corresponding parental strain. The crystal delta-endotoxin produced by the mutant Bacillus thuringiensis will have an activity directed towards the same pest(s) as its parental Bacillus thuringiensis crystal delta-endotoxin. The invention further relates to a method for producing such a mutant, compositions comprising such a mutant as well as methods for controlling a pest(s) using these compositions.

The invention discloses a recombinant canine influenza virus strain and a preparation method thereof as well as a vaccine prepared from the recombinant canine influenza virus strain. A recombinant canine influenza virus comprises HA and NA genes of a H3N2 subtype canine influenza virus and six internal genes of a H9N2 avian influenza virus including PB2, PB1, PA, NP, M and NS. The recombinant canine influenza virus strain disclosed by the invention is named after rH3N2-DL. The preservation number of the recombinant canine influenza virus strain disclosed by the invention is CGMCC No.8162. The invention further discloses the preparation method of the recombinant canine influenza virus and the vaccine prepared from the recombinant canine influenza virus. Compared with the parental strain, the recombinant canine influenza virus disclosed by the invention has high virus titer and blood congeal titer both on chick embryos and MDCK cells. Animal experimental results show that the vaccine prepared from the recombinant canine influenza virus has good immunogenicity and protective efficacy.

The present invention relates to novel strains of microorganisms with oxygen-regulated metabolism. The microorganisms have higher growth rates and are more efficient than parental strains. The microorganisms may be used to produce a variety of products of interests, such as recombinant proteins, nucleic acids, such as DNA, amino acids, and chemicals.